Press releases
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
- Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
- Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
- Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
- Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
- Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
- Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
- Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023
More ▼
Key statistics
As of last trade Akeso Inc (9926:HKG.HS) traded at 49.70, -9.64% below its 52-week high of 55.00, set on Mar 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 50.20 |
---|---|
High | 50.65 |
Low | 49.30 |
Bid | 49.60 |
Offer | 49.70 |
Previous close | 49.20 |
Average volume | 4.05m |
---|---|
Shares outstanding | 865.86m |
Free float | 634.96m |
P/E (TTM) | 18.97 |
Market cap | 43.03bn HKD |
EPS (TTM) | 2.62 HKD |
Data delayed at least 15 minutes, as of May 16 2024.
More ▼